Page last updated: 2024-10-30

leflunomide and Anti-Glomerular Basement Membrane Disease

leflunomide has been researched along with Anti-Glomerular Basement Membrane Disease in 1 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Anti-Glomerular Basement Membrane Disease: An autoimmune disease of the KIDNEY and the LUNG. It is characterized by the presence of circulating autoantibodies targeting the epitopes in the non-collagenous domains of COLLAGEN TYPE IV in the basement membranes of kidney glomeruli (KIDNEY GLOMERULUS) and lung alveoli (PULMONARY ALVEOLI), and the subsequent destruction of these basement membranes. Clinical features include pulmonary alveolar hemorrhage and glomerulonephritis.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chow, KM1
Szeto, CC1

Other Studies

1 other study available for leflunomide and Anti-Glomerular Basement Membrane Disease

ArticleYear
Leflunomide and anti-glomerular basement membrane glomerulonephritis: comment on the letter by Bruyn et al.
    Arthritis and rheumatism, 2004, Volume: 50, Issue:1

    Topics: Animals; Anti-Glomerular Basement Membrane Disease; Humans; Immunosuppressive Agents; Isoxazoles; Le

2004